Thermo Fisher Scientific Inc. (NYSE:TMO) Receives $650.05 Average PT from Analysts

Thermo Fisher Scientific Inc. (NYSE:TMO) has been assigned a consensus recommendation of “Moderate Buy” from the twenty-two research firms that are currently covering the stock, MarketBeat Ratings reports. Five analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $650.05.

Several equities analysts recently issued reports on TMO shares. Stifel Nicolaus lowered their price target on Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating on the stock in a research note on Thursday, October 24th. Redburn Atlantic began coverage on shares of Thermo Fisher Scientific in a research note on Monday, October 14th. They set a “buy” rating and a $680.00 price target for the company. TD Cowen boosted their price target on Thermo Fisher Scientific from $656.00 to $686.00 in a research note on Tuesday, October 22nd. Scotiabank assumed coverage on Thermo Fisher Scientific in a research note on Monday, December 23rd. They set a “sector perform” rating and a $605.00 price objective for the company. Finally, Stephens initiated coverage on shares of Thermo Fisher Scientific in a research note on Tuesday, October 1st. They issued an “overweight” rating and a $680.00 target price on the stock.

Thermo Fisher Scientific Stock Up 1.8 %

Thermo Fisher Scientific stock opened at $532.02 on Thursday. The firm has a market cap of $203.50 billion, a price-to-earnings ratio of 33.36, a P/E/G ratio of 3.54 and a beta of 0.76. The firm has a fifty day moving average price of $530.72 and a two-hundred day moving average price of $568.68. Thermo Fisher Scientific has a fifty-two week low of $493.30 and a fifty-two week high of $627.88. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.63 and a quick ratio of 1.26.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share for the quarter, beating the consensus estimate of $5.25 by $0.03. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. The firm had revenue of $10.60 billion during the quarter, compared to the consensus estimate of $10.63 billion. During the same quarter in the prior year, the company earned $5.69 EPS. The firm’s revenue for the quarter was up .2% compared to the same quarter last year. As a group, analysts forecast that Thermo Fisher Scientific will post 21.68 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, January 15th. Stockholders of record on Friday, December 13th will be paid a $0.39 dividend. This represents a $1.56 annualized dividend and a dividend yield of 0.29%. The ex-dividend date of this dividend is Friday, December 13th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 9.78%.

Thermo Fisher Scientific declared that its board has initiated a stock buyback program on Friday, November 15th that authorizes the company to repurchase $4.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to repurchase up to 2% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s leadership believes its shares are undervalued.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the business’s stock in a transaction dated Friday, October 25th. The stock was sold at an average price of $560.16, for a total value of $168,048.00. Following the completion of the transaction, the executive vice president now directly owns 16,663 shares of the company’s stock, valued at approximately $9,333,946.08. The trade was a 1.77 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction dated Monday, October 28th. The stock was sold at an average price of $554.29, for a total value of $5,542,900.00. Following the sale, the chief executive officer now directly owns 121,192 shares in the company, valued at approximately $67,175,513.68. This represents a 7.62 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 47,150 shares of company stock worth $25,954,465. 0.34% of the stock is owned by insiders.

Institutional Trading of Thermo Fisher Scientific

A number of large investors have recently bought and sold shares of the business. Verus Capital Partners LLC raised its holdings in shares of Thermo Fisher Scientific by 14.0% during the second quarter. Verus Capital Partners LLC now owns 456 shares of the medical research company’s stock worth $252,000 after acquiring an additional 56 shares during the period. Versor Investments LP bought a new stake in shares of Thermo Fisher Scientific in the second quarter valued at about $664,000. Midland Wealth Advisors LLC boosted its position in shares of Thermo Fisher Scientific by 8.0% during the second quarter. Midland Wealth Advisors LLC now owns 812 shares of the medical research company’s stock worth $449,000 after buying an additional 60 shares during the period. Founders Financial Securities LLC raised its position in Thermo Fisher Scientific by 0.9% in the 2nd quarter. Founders Financial Securities LLC now owns 2,058 shares of the medical research company’s stock valued at $1,138,000 after buying an additional 19 shares during the last quarter. Finally, Cozad Asset Management Inc. boosted its position in Thermo Fisher Scientific by 3.6% during the 2nd quarter. Cozad Asset Management Inc. now owns 10,967 shares of the medical research company’s stock worth $6,065,000 after acquiring an additional 382 shares during the last quarter. 89.23% of the stock is owned by institutional investors.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.